PYX-201 is a monoclonal antibody conjugated commercialized by Pyxis Oncology, with a leading Phase I program in Thyroid Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of PYX-201’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for PYX-201 is expected to reach an annual total of $63 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
PYX-201 is under development for the treatment of non-small cell lung cancer, triple-negative breast cancer, solid tumors, metastatic breast cancer, head and neck cancer squamous cell carcinoma, pancreatic ductal adenocarcinoma, ovarian cancer, hepatocellular carcinoma, soft tissue sarcoma and kidney cancer (renal cell cancer) and thyroid cancer. The drug candidate is a monoclonal antibody conjugate which acts by targeting oncofetal fibronectin. It is being developed based on Flexible Antibody Conjugation Technology (FACT). It is administered by intravenous route.
Pyxis Oncology Overview
Pyxis Oncology is an immuno-oncology company that develops antibody drug conjugates (ADC) and immunotherapies for cancer. It is investigating PYX-201 to treat solid tumors; PYX-202 program to treat soft tissue sarcoma; and PYX-203 drug against myelodysplastic syndromes (MDS) and acute myeloid leukemia. The company utilizes its proprietary flexible antibody conjugation technology (FACT) platform to develop ADCs. Pyxis Oncology’s platform technology analyses promising tumor targets and acquire highly specific antibodies to these tumor targets. It carries out research and development with pharmaceutical and biotech companies to develop innovative medicines. Pyxis Oncology is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$123.5 million in FY2022, compared to an operating loss of US$69.7 million in FY2021. The net loss of the company was US$120.7 million in FY2022, compared to a net loss of US$76 million in FY2021.
For a complete picture of PYX-201’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.